XTLB
xtl biopharmaceuticals ltd. (nasdaq:xtlb, tase:xtlb.ta) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. the company’s lead drug candidate, hcdr1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (sle). treatments currently on the market for sle are not effective enough for most patients and some have significant side effects. robust clinical data on hcdr1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.
Looks like X.T.L. Biopharmaceuticals Ltd. doesn't offer shareholder perks yet... tell X.T.L. Biopharmaceuticals Ltd. (Tii:XTLB) you want perks by adding your email below.
TiiCKER offers a completely personalized experience and first-ever way to view your stock portfolio, trade for free and invest in new companies while viewing your perks in one place!
Create a profile
Connect accounts
Discover brands
Collect rewards
Joshua Levine
New York, New York
1
xtl biopharmaceuticals ltd. (nasdaq:xtlb, tase:xtlb.ta) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. the company’s lead drug candidate, hcdr1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (sle). treatments currently on the market for sle are not effective enough for most patients and some have significant side effects. robust clinical data on hcdr1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.
TiiCKER was created for fan-first, brand-first public companies—with exclusive perks served-up weekly to shareholders. Own stock? Connect your brokerage account to view more than 130 perks waiting for you right now!